Safety and Efficacy Study BRIMOCHOL™ PF and Carbachol PF in Subjects With Emmetropic Phakic or Pseudophakic Presbyopia

• Status: Not yet recruiting
• Trial end date: 2023-01-05
• Target enrollment: 0
• Participant gender: All

Summary

Safety and Efficacy Study of BRIMOCHOL™ PF and Carbachol PF in Subjects With Emmetropic Phakic and Pseudophakic Presbyopia

• Phase: Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Visus Therapeutics
• Treatments: Brimonidine Tartrate; Carbachol

Criteria

Inclusion Criteria:

• Male or female in good general health

• Must have presbyopia

Exclusion Criteria:

• History of allergic reaction to the study drug or any of its components

• Any disease or medical condition that, in the opinion of the Investigator, would prevent the subject from participating in the study or might confound study results